The lung cancer molecular biomarker market is projected to grow from USD 6.2 billion in 2026 to USD 17.3 billion by 2036, at a CAGR of 10.8%. EGFR will dominate with a 28.0% market share, while therapy selection will lead the application segment with a 48.0% share.